Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CRN04894 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose (Part 1) | EXPERIMENTAL | - |
| Multiple Ascending Dose (Part 2) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CRN04894 Oral Solution | DRUG | CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist. |
| Placebo Oral Solution | DRUG | Placebo |
Inclusion Criteria: * Females must be either postmenopausal or surgically sterile; or using stable and permitted highly effective method of contraception - use of oral hormonal contraceptives are not allowed during the study * Male subjects must be surgically sterile or agree to use highly effectiv...
CRN04894 is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its safety, tolerability, and pharmacokinetics in healthy adult participants. The drug is not approved for any condition and remains in early-stage clinical research.
CRN04894 is being developed by Crinetics Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker CRNX. The company is conducting clinical research on this investigational small molecule, which is currently in Phase 1 development.
CRN04894 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities and is still undergoing early-stage clinical evaluation in healthy volunteers.
CRN04894 has one completed Phase 1 clinical trial, identified as NCT06048887, titled "Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers." This randomized, double-blind, controlled study enrolled 88 participants in the United States and evaluated the drug in healthy adults aged 18 years and older.
No, CRN04894 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed Phase 1 trial in healthy volunteers is part of early-stage research, and the drug has not yet received regulatory approval for any use.